Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 6/20 | 0.49 |
| ▸ | ITGA4 | P13612 | 6/20 | 0.49 |
| ▸ | ITGB7 | P26010 | 4/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.43 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | CCKAR | P32238 | 5/20 | 0.42 |
| ▸ | CCKBR | P32239 | 5/20 | 0.42 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.42 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5926531 | 0.90 | ITGB1 (0.51) | ITGB1ITGA4ITGB7CA1CA2 | |
| SCHEMBL5927468 | 0.87 | CTSA (0.45) | — | |
| SCHEMBL5926611 | 0.86 | MMP1 (0.51) | ITGB1ITGA4ITGB7CA1CA2 | |
| SCHEMBL5926499 | 0.85 | ITGB1 (0.47) | ITGB1ITGA4ITGB7CA1CA2 | |
| SCHEMBL8337901 | 0.85 | ITGB1 (0.47) | ITGB1ITGA4ITGB7CA1CA2 | |
| SCHEMBL5926666 | 0.82 | ITGB1 (0.54) | ITGB1ITGA4ITGB7ERAP1PTPN1 | |
| SCHEMBL8337957 | 0.82 | ITGB1 (0.54) | ITGB1ITGA4ITGB7ERAP1PTPN1 | |
| SCHEMBL8337414 | 0.81 | ITGB1 (0.44) | ITGB1ITGA4ITGB7CA2ADAMTS5 | |
| SCHEMBL5926711 | 0.81 | ITGB1 (0.50) | ITGB1ITGA4ITGB7CA1CA2 | |
| SCHEMBL5927188 | 0.81 | ITGB1 (0.52) | ITGB1ITGA4ITGB7ERAP1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | ITGB1 240/4885ITGA4 312/4885ITGB7 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.